Last data update: Dec 02, 2024. (Total: 48272 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Dorough Layne[original query] |
---|
COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021.
CDC COVID-19 Vaccine Breakthrough Case Investigations Team , Birhane Meseret , Bressler Sara , Chang Gregory , Clark Thomas , Dorough Layne , Fischer Marc , Watkins Louise Francois , Goldstein Jason M , Kugeler Kiersten , Langley Gayle , Lecy Kristin , Martin Stacey , Medalla Felicita , Mitruka Kiren , Nolen Leisha , Sadigh Katrin , Spratling Robin , Thompson Gail , Trujillo Alma . MMWR Morb Mortal Wkly Rep 2021 70 (21) 792-793 COVID-19 vaccines are a critical tool for controlling the ongoing global pandemic. The Food and Drug Administration (FDA) has issued Emergency Use Authorizations for three COVID-19 vaccines for use in the United States.* In large, randomized-controlled trials, each vaccine was found to be safe and efficacious in preventing symptomatic, laboratory-confirmed COVID-19 (1-3). Despite the high level of vaccine efficacy, a small percentage of fully vaccinated persons (i.e. received all recommended doses of an FDA-authorized COVID-19 vaccine) will develop symptomatic or asymptomatic infections with SARS-CoV-2, the virus that causes COVID-19 (2-8). |
Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020.
Tenforde MW , Kim SS , Lindsell CJ , Billig Rose E , Shapiro NI , Files DC , Gibbs KW , Erickson HL , Steingrub JS , Smithline HA , Gong MN , Aboodi MS , Exline MC , Henning DJ , Wilson JG , Khan A , Qadir N , Brown SM , Peltan ID , Rice TW , Hager DN , Ginde AA , Stubblefield WB , Patel MM , Self WH , Feldstein LR , IVY Network Investigators , CDC COVID-19 Response Team , Dorough Layne , Dzuris Nicole , Griggs Eric P , Kassem Ahmed M , Marcet Paula L , Ogokeh Constance E , Sciarratta Courtney N Siddula Akshita , Smith Emily R , Wu Michael J . MMWR Morb Mortal Wkly Rep 2020 69 (30) 993-998 Prolonged symptom duration and disability are common in adults hospitalized with severe coronavirus disease 2019 (COVID-19). Characterizing return to baseline health among outpatients with milder COVID-19 illness is important for understanding the full spectrum of COVID-19-associated illness and tailoring public health messaging, interventions, and policy. During April 15-June 25, 2020, telephone interviews were conducted with a random sample of adults aged ≥18 years who had a first positive reverse transcription-polymerase chain reaction (RT-PCR) test for SARS-CoV-2, the virus that causes COVID-19, at an outpatient visit at one of 14 U.S. academic health care systems in 13 states. Interviews were conducted 14-21 days after the test date. Respondents were asked about demographic characteristics, baseline chronic medical conditions, symptoms present at the time of testing, whether those symptoms had resolved by the interview date, and whether they had returned to their usual state of health at the time of interview. Among 292 respondents, 94% (274) reported experiencing one or more symptoms at the time of testing; 35% of these symptomatic respondents reported not having returned to their usual state of health by the date of the interview (median = 16 days from testing date), including 26% among those aged 18-34 years, 32% among those aged 35-49 years, and 47% among those aged ≥50 years. Among respondents reporting cough, fatigue, or shortness of breath at the time of testing, 43%, 35%, and 29%, respectively, continued to experience these symptoms at the time of the interview. These findings indicate that COVID-19 can result in prolonged illness even among persons with milder outpatient illness, including young adults. Effective public health messaging targeting these groups is warranted. Preventative measures, including social distancing, frequent handwashing, and the consistent and correct use of face coverings in public, should be strongly encouraged to slow the spread of SARS-CoV-2. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Dec 02, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure